Table 3.
Identification of potential biomarkers related to development of diabetic cardiomyopathy rats.
| No. | tR (min) | Mass-to-charge (m/z) ratios | Metabolites | DCM vs. CON | MET 200 vs. DCM | BER 10 vs. DCM | BER 30 vs. DCM | |||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| VIP values | P-values | FC values | P-values | FC values | P-values | FC values | P-values | FC values | ||||
| 1 | 12.0796 | 786.60079 | PC(18:0/18:2) | 3.006781 | 1.32E-07 | 3.0068 | 0.327604 | 1.0807 | 0.013098 | 0.7619 | 0.027139 | 0.6058 |
| 2 | 1.5160 | 520.34032 | PC(18:2/0:0) | 2.690564 | 0.000507 | 2.6906 | 0.555070 | 1.1357 | 0.016675 | 0.5969 | 0.025931 | 0.5989 |
| 3 | 3.0185 | 466.32977 | PE(P-18:0/0:0) | 3.347361 | 1.62E-06 | 3.3474 | 0.307410 | 0.8457 | 0.005106 | 0.7163 | 0.450433 | 0.9335 |
| 4 | 1.5517 | 478.29289 | PE(18:2/0:0) | 2.142614 | 0.022380 | 2.1426 | 0.767972 | 1.0863 | 0.029045 | 0.4881 | 0.024280 | 0.4366 |
| 5 | 8.7803 | 705.59059 | SM(d18:0/16:0) | 3.805205 | 1.21E-06 | 3.8052 | 0.245808 | 0.8385 | 0.000135 | 0.5423 | 0.000020 | 0.3671 |
| 6 | 8.3575 | 729.59056 | SM(d18:1/18:1) | 2.043793 | 5.34E-05 | 2.0438 | 0.163162 | 0.8610 | 0.603399 | 0.9569 | 0.416094 | 0.9196 |
| 7 | 8.1461 | 706.53886 | PC(16:0/14:0) | 3.403970 | 3.14E-06 | 0.2938 | 0.000664 | 0.5270 | 0.609048 | 1.0346 | 0.796824 | 1.4075 |
| 8 | 10.8241 | 734.57009 | PC(16:0/16:0) | 2.064071 | 2.48E-06 | 0.4845 | 0.011311 | 0.7546 | 0.394074 | 0.9302 | 0.746697 | 1.0889 |
| 9 | 8.7446 | 782.56980 | PC(16:0/20:4) | 3.218626 | 3.24E-05 | 0.3107 | 0.197687 | 0.6865 | 0.048580 | 1.3616 | 0.211812 | 1.5514 |
| 10 | 11.8139 | 836.61668 | PC(18:0/22:5) | 2.477047 | 0.000951 | 0.4037 | 0.144162 | 0.5809 | 0.018528 | 1.6424 | 0.074504 | 2.3522 |
| 11 | 1.3903 | 544.34034 | PC(20:4/0:0) | 4.333849 | 7.64E-05 | 0.2307 | 0.736446 | 0.8593 | 0.017967 | 1.8425 | 0.077411 | 3.1387 |
| 12 | 11.6239 | 810.60078 | PC(20:4/18:0) | 2.534677 | 0.000301 | 0.3945 | 0.327411 | 0.7201 | 0.007459 | 1.7659 | 0.128390 | 1.7546 |
| 13 | 9.0317 | 808.58519 | PC(20:4/18:1) | 2.578941 | 0.000242 | 0.3878 | 0.218952 | 0.6849 | 0.035153 | 1.4237 | 0.197382 | 1.6132 |
| 14 | 7.3106 | 806.56949 | PC(20:4/18:2) | 2.010264 | 0.001226 | 0.4974 | 0.153197 | 0.6732 | 0.153344 | 1.2372 | 0.917770 | 1.0087 |
| 15 | 10.8527 | 834.60065 | PC(20:4/20:2) | 3.423473 | 0.000324 | 0.2921 | 0.124597 | 0.5275 | 0.010437 | 1.8687 | 0.100724 | 2.6785 |
| 16 | 6.8407 | 830.56954 | PC(20:4/20:4) | 2.833827 | 8.79E-05 | 0.3529 | 0.031543 | 0.5630 | 0.052507 | 1.3728 | 0.225158 | 1.6431 |
| 17 | 9.2859 | 740.52268 | PE(20:4/16:0) | 1.919220 | 8.79E-05 | 0.5210 | 0.059134 | 0.7180 | 0.207394 | 1.1066 | 0.781551 | 1.1054 |
tR, retention time; VIP, variable important in the projection; FC, folder change; PC, phosphatidylcholine; PE, phosphatidylethanolamine; SM, sphingolipid; CON, control group; DCM, diabetic cardiomyopathy model group; MET 200, DCM + Metformin 200 mg/kg group; BER 10, DCM + Berberine 10 mg/kg group; BER 30, DCM + Berberine 30 mg/kg group.